Dev48
Language
  • About
  • Services
  • Industries
  • Technologies
  • Articles
  • Contacts
Book a call
    Home/Articles/Francis van parys outlines our priorities for customers in oxford nanopores next 2
Dev48
info@dev48.org+375 29 320-40-96WhatsApp@isky_by

© 2026 · All rights reserved.

Francis Van Parys outlines our priorities for customers in Oxford Nanopore's next phase of growth

Source: Oxford Nanopore Technologies•September 28, 2026 at 11:58 PM

Francis Van Parys outlines our priorities for customers in Oxford Nanopore's next phase of growth

As Oxford Nanopore announces its H1 2026 results, CEO Francis Van Parys has shared a new video message with customers, partners and the wider nanopore community, setting out his priorities for the company's next chapter.

Six months into the role, Francis reflects on what he has learned from conversations with customers around the world and how that feedback is shaping Oxford Nanopore's focus for the years ahead.

At the heart of his message is the goal of helping more customers unlock the full potential of nanopore technology in routine use.

While Oxford Nanopore's platform continues to drive breakthroughs across research, biopharma and clinical, Francis explains how the company is working to make its solutions easier to adopt, integrate and scale. Francis also reaffirms the company's commitment to the research community, whose work continues to expand the possibilities of Oxford Nanopore sequencing.

Looking ahead, he discusses ongoing investment in the technologies, software, expertise and support that help customers generate value from nanopore data, as well as the role customers and partners will play in shaping the future of the platform.

Watch the video below to hear Francis's reflections on his first six months as CEO and his vision for the next phase of Oxford Nanopore's journey.

← All articles

What this article says

More in HealthTech & MedTech

All →
Building the Foundation for Agentic Safety | Veeva
Veeva Systems

Building the Foundation for Agentic Safety | Veeva

How athenaOne® unifies AI across the clinical workflow
Athenahealth

How athenaOne® unifies AI across the clinical workflow

From months to days: how nanopore sequencing is transforming genomic investigations at VCGS
Oxford Nanopore

From months to days: how nanopore sequencing is transforming genomic investigations at VCGS

Oxford Nanopore marks a decade of sequencing in space
Oxford Nanopore

Oxford Nanopore marks a decade of sequencing in space

Inovalon To Acquire Intelligent Medication Management Company DrFirst
Inovalon

Inovalon To Acquire Intelligent Medication Management Company DrFirst

Sonova HY 2026/27 results: Raising full-year guidance after strong first half
Sonova

Sonova HY 2026/27 results: Raising full-year guidance after strong first half

More from Oxford Nanopore

From months to days: how nanopore sequencing is transforming genomic investigations at VCGS
Oxford Nanopore

From months to days: how nanopore sequencing is transforming genomic investigations at VCGS

Oxford Nanopore marks a decade of sequencing in space
Oxford Nanopore

Oxford Nanopore marks a decade of sequencing in space

mSCAPE: a national collaboration using metagenomics to protect public health
Oxford Nanopore

mSCAPE: a national collaboration using metagenomics to protect public health

Science Unlocked: publication picks from September 2026
Oxford Nanopore

Science Unlocked: publication picks from September 2026

Appointment of Chief Business Development Officer
Oxford Nanopore

Appointment of Chief Business Development Officer

RAPID answers for rare diseases
Oxford Nanopore

RAPID answers for rare diseases